Integra LifeSciences Holdings Corporation
HealthcareNASDAQ:IART · NASDAQ Global Select
+$0.26 today
Vol 0.51M · Avg 0.96M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$1.6B of revenue converted into -$495.8M of net income for the selected period. Gross margin is 53.3% and net margin is -29.8%, showing how much revenue survives after costs and taxes. EPS is $-6.48, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6B +1.5% | $1.6B +4.5% | $1.5B -1.0% | $1.6B +1.0% | $1.5B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $790.0M +8.4% | $728.5M +10.9% | $656.8M +11.8% | $587.4M -1.7% | $597.8M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $845.2M -4.2% | $882.1M -0.3% | $884.7M -8.8% | $970.3M +2.7% | $944.6M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 51.7% -3.1pp | 54.8% -2.6pp | 57.4% -4.9pp | 62.3% +1.0pp | 61.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $99.0M -14.2% | $115.4M +10.7% | $104.2M +3.0% | $101.2M +8.8% | $93.1M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $699.7M -2.4% | $717.0M +9.2% | $656.6M +6.5% | $616.3M -3.3% | $637.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $776.9M -9.0% | $853.6M +10.4% | $773.2M +5.7% | $731.4M -2.1% | $747.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $151.0M +7.5% | $140.5M +13.8% | $123.5M +2.0% | $121.1M -2.1% | $123.7M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$326.2M -268.8% | $193.3M -24.5% | $256.0M -33.4% | $384.6M +5.0% | $366.3M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -19.9% -31.9pp | 12.0% -4.6pp | 16.6% -8.1pp | 24.7% +0.9pp | 23.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | $68.3M +140.5% | $28.4M -74.5% | $111.5M -53.3% | $238.9M +21.1% | $197.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 4.2% +2.4pp | 1.8% -5.5pp | 7.2% -8.1pp | 15.3% +2.6pp | 12.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $18.5M -7.8% | $20.0M +16.5% | $17.2M +44.3% | $11.9M +76.9% | $6.7M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $86.3M +22.1% | $70.6M +37.5% | $51.4M +3.6% | $49.6M -1.6% | $50.4M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$631.8M -1254.4% | -$46.6M -53.2% | -$30.5M -21.7% | -$25.0M -243.4% | $17.4M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$563.5M -2989.9% | -$18.2M -122.5% | $81.1M -62.1% | $213.9M -0.4% | $214.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -34.5% -33.3pp | -1.1% -6.4pp | 5.3% -8.5pp | 13.7% -0.2pp | 13.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$47.0M -316.4% | -$11.3M -184.7% | $13.3M -60.0% | $33.3M -26.9% | $45.6M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$516.5M -7337.7% | -$6.9M -110.3% | $67.7M -62.5% | $180.6M +6.8% | $169.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | -31.6% -31.2pp | -0.4% -4.8pp | 4.4% -7.2pp | 11.6% +0.6pp | 11.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$7 -7361.2% | -$0 -110.4% | $1 -60.1% | $2 +9.0% | $2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$7 -7361.2% | -$0 -110.7% | $1 -61.1% | $2 +9.1% | $2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $76.8M -0.3% | $77.0M -1.5% | $78.2M -5.8% | $83.0M -2.0% | $84.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $76.8M -0.3% | $77.0M -4.1% | $80.3M -3.8% | $83.5M -2.3% | $85.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Septerna, Inc.
NASDAQ:SEPN
$1.62B
Fortrea Holdings Inc.
NASDAQ:FTRE
$1.56B
Butterfly Network, Inc.
NYSE:BFLY
$1.45B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.19B
Tandem Diabetes Care, Inc.
NASDAQ:TNDM
$1.14B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.09B
InMode Ltd.
NASDAQ:INMD
$817.88M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$722.58M
Myriad Genetics, Inc.
NASDAQ:MYGN
$408.96M
Pacific Biosciences of California, Inc.
NASDAQ:PACB
$406.89M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does IART generate?
Integra LifeSciences Holdings Corporation (IART) reported $1.64B of revenue in fiscal 2025.
Is IART profitable?
Integra LifeSciences Holdings Corporation (IART) reported -$516,474,000.00 of net income, with a net margin of -31.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.